Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products …